At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the immune system, and immune cells produce a potentially lifesaving antibody ...

In biology textbooks and beyond, the human genome and DNA therein typically are taught in only one dimension. While it can be ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Advanced imaging technologies are uncovering surprising roles for CD8+ T cells—not just in immune defense, but also in supporting tissue repair and regeneration.

Bispecific T cell engagers (TcEs) that are able to simultaneously bind to epitopes on cancer cells and T cells are a versatile, highly potent, and economical immunotherapeutic tool (1). TcEs are ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients with relapsed or refractory mantle cell lymphoma in a phase 1/2 study.In ...

A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.Rare subsequent cancers develop ...

Medicine has entered a new era in which the fundamental components of life—genes and cells—are being used to treat disease. Engineering a patient's own T cells to express chimeric antigen receptors ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o ...

Abstract Suspected adverse reactions following chimeric antigen receptor T-cell (CAR T) treatment include more and more cases of secondary T-cell malignancies.